Orthocell (OCC) H1 2026 earnings summary

Executive summary

• Achieved 48% year-over-year revenue growth to $6.2m for the half-year ended 31 December 2025, driven by accelerating commercial momentum and the US launch of Remplir.

• Expanded into Canada and Hong Kong, and submitted regulatory applications for the EU and UK, broadening future market opportunities.

• Strengthened balance sheet with a $30m capital raise, ending the period with $49.4m in cash and term deposits.

• Enhanced leadership with new CFO, CCO, and a Non-Executive Director to support global scale-up.

Financial highlights

• Revenue rose to $6.2m from $4.2m in 1H FY25, marking seven consecutive quarters of record revenue and a CQGR of 10-11% since FY24.

• Gross profit increased to $2.98m (vs $1.83m prior year); however, net loss widened to $5.2m (vs $1.3m prior year).

• Cash and term deposits totaled $49.4m at 31 December 2025, up from $28.6m at 30 June 2025.

• Operating cash outflow was $9.0m, up from $5.6m in the prior period.

• Share-based payments expense increased to $1.4m from $0.2m year-over-year.

Outlook and guidance

• Anticipates continued revenue expansion as US sales scale and new international markets contribute throughout CY26.

• Expects regulatory approval in the EU and UK in 3Q CY26, unlocking a significant market opportunity.

• Well-capitalized position enables acceleration of global growth strategy.